TNG917 / Tango Therap - LARVOL DELTA

TNG917: a potent and orally active inhibitor of euchromatic histone lysine methyltransferases (EHMT1/2) for the treatment of immune-cold tumors (SITC 2024) - "In addition, TNG917 induced CD45 infiltration and CXCL10 cytokine secretion in human patient-derived xenograft (PDX) organoids co-cultured with human dermal fibroblasts (HDF) and PBMCs. Conclusions In summary, our in vitro and in vivo studies provide a rationale for the clinical development path of TNG917, in combination with checkpoint inhibition, in patients with immune-cold tumors."

IO biomarker • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • CXCL10 • EHMT2 • PD-L1 • PTPRC

TNG917 is a clinical-grade, potent and selective inhibitor of EHMT1/2 for the treatment of immune cold tumors (AACR 2024) - "In humanized and syngeneic mouse models, treatment with TNG917 in combination with anti-PD1 promoted a T-cell-infiltrated tumor microenvironment, led to significant anti-tumor activity, and resulted in survival benefit. In summary, our in vitro and in vivo studies provide a rationale for the clinical development path of TNG917, in combination with checkpoint inhibition, in patients with immune cold tumors."

Clinical • IO biomarker • Oncology • PD-L1

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) - "Tango Therapeutics, Inc...today announced that one abstract has been selected for an oral minisymposium and seven abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor